Sign In
Buy IDRSF
$5.75
+0 (+0%)
At Close: Jun 02, 2026
Idorsia shares new analyses of daridorexant for patients with insomnia at World Sleep 2025
11:45am, Wednesday, 10'th Sep 2025
Allschwil, Switzerland – September 10, 2025 Idorsia Ltd (SIX: IDIA) shares new analyses of daridorexant for patients with insomnia and further characterizes insomnia disorder at World Sleep 2025, de
Idorsia Ltd (IDRSF) TRYVIO Investor Q&A Webcast And Conference Call (Transcript)
12:30pm, Monday, 08'th Sep 2025
Idorsia Ltd (OTC:IDRSF) TRYVIO Investor Q&A Webcast and Conference Call Company Participants Srishti Gupta - CEO & Executive Director Martine Clozel - Executive VP, Chief Scientific Officer & Head of
Idorsia highlights very low real-world abuse potential of DORA class for insomnia treatment at WSC 2025
11:45am, Monday, 08'th Sep 2025
Allschwil, Switzerland – September 8, 2025 Idorsia Ltd (SIX: IDIA) presented real-world data from the FDA Adverse Event Reporting System (FAERS) at the World Sleep 2025, evaluating abuse-related adv
Multi-phase program to standardize treatment, generate real-world evidence, and explore AI-powered tools to improve outcomes for hypertension patients ALLSCHWIL, Switzerland and RADNOR, Pa. , Sept. 5,
Allschwil, Switzerland & Radnor, Philadelphia – September 5, 2025 Idorsia Ltd (SIX: IDIA) announces a first-of-its-kind initiative with the Stanford Hypertension Center and Duke Heart Center to laun
Invitation to Idorsia's aprocitentan (TRYVIO/JERAYGO) investor Q&A webcast and conference call
11:45am, Wednesday, 03'rd Sep 2025
Idorsia will host a live investor Q&A webcast and conference call following the publication of the OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only hypertensio
Idorsia furthers the science of sleep and insomnia at World Sleep 2025
11:45am, Monday, 01'st Sep 2025
Allschwil, Switzerland – September 1, 2025 Idorsia Ltd (SIX: IDIA) continues its commitment to furthering the science of sleep and insomnia with a symposium and eight poster presentations at World S
Idorsia's TRYVIO – First FDA-approved therapy to target the endothelin pathway for systemic hypertension
01:00am, Thursday, 28'th Aug 2025
Allschwil, Switzerland – August 28, 2025 Idorsia Ltd (SIX: IDIA) releases an OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only hypertension therapy targeting th
Idorsia publishes end results of repurchase offer for its 2025 and 2028 convertible bonds
01:00am, Tuesday, 19'th Aug 2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – August 19, 2025 Idorsia Ltd (SIX: IDIA) announces the end results of the repurchase offer for its outstanding CHF 204* million c
Idorsia publishes interim results of repurchase offer for its 2025 and 2028 convertible bonds
01:00am, Monday, 11'th Aug 2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – August 11, 2025 Idorsia Ltd (SIX: IDIA) announces the interim results of the repurchase offer for its outstanding CHF 204* million
Idorsia Ltd (IDRSF) Q2 2025 Earnings Call Transcript
06:32pm, Wednesday, 30'th Jul 2025
Idorsia Ltd (OTC:IDRSF) Q2 2025 Earnings Conference Call July 30, 2025 8:00 AM ET Company Participants Andrew Jones - Senior VP, Head of Corporate Communications & Investor Relations Arno Groenewoud -
Strong sales acceleration of QUVIVIQ drives Idorsia toward profitability – H1 2025 results
01:00am, Wednesday, 30'th Jul 2025
Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ™ (daridorexant): Strong performance and sales acceleration with total net sales of CHF 58 million in H1 2025 and increase of 145% compared to the
Invitation to Idorsia's HY 2025 Financial Reporting webcast and conference call with our new CEO Srishti Gupta
01:45pm, Wednesday, 23'rd Jul 2025
Idorsia will publish its Half Year 2025 Financial Reporting on Wednesday July 30, at 07:00 CEST. An investor webcast and conference call will be held to discuss the results on the same day.
A factory in a lab: Idorsia's breakthrough synthetic glycan vaccine platform validated for the first time in humans
01:00am, Monday, 30'th Jun 2025
Ad hoc announcement pursuant to Art. 53 LR Potential first-ever vaccine directed against C.
Idorsia launches repurchase offer for its 2025 and 2028 convertible bonds
01:20am, Wednesday, 25'th Jun 2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – June 25, 2025 Idorsia Ltd (SIX: IDIA) today announced the launch of the repurchase offer to the holders of its outstanding CHF 200
